FDA Inspection
Hospira, Inc., A Pfizer CompanyHospira, Inc., A Pfizer Company – FDA Inspection, Mar 10, 2026
Record Details
This FDA Inspection record concerns Hospira, Inc., A Pfizer Company, with an inspection on March 10, 2026, issued by the Kansas City District Office, covering human drugs.
View Company Profile
ID · 98e3997c-83d5-4c09-9ab4-1afba7f97ca3
Inspection Facts
- Inspection number
- 1310592
- FDA center
- Human Drugs
- Outcome
- Form 483 issued
Other FDA inspections of Hospira, Inc., A Pfizer Company
19| Date | Classification | Office | Project area |
|---|---|---|---|
| January 17, 2025 | VAI | Kansas City District Office | Drug Quality Assurance |
| March 27, 2024 | NAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
| June 30, 2023 | Not classified | Kansas City District Office | |
| January 17, 2020 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 15, 2018 | OAI | Center for Veterinary Medicine | Monitoring of Marketed Animal Drugs, Feed, and Devices |
Other documents for Hospira, Inc., A Pfizer Company
- FDA Inspection 1255699 - 2025-01-17
- FDA Inspection 1229140 - 2024-03-27
- FDA Inspection 1209308 - 2023-06-30
- FDA Inspection 1115467 - 2020-01-17
- FDA Inspection 1064827 - 2018-08-15
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.